Knockdown of SPOP or expression of prostate cancer-associated SPOP mutants sensitized prostate cancer cells to PARP inhibitor, olaparib, as was seen in BRCA1-depleted cells [36,61]. The gene discussed is BRCA1; the disease is prostate carcinoma.